dc.contributor.author | Basaranoglu, Sevgen Tanir | |
dc.contributor.author | Oncel, Eda Karadag | |
dc.contributor.author | Aykac, Kubra | |
dc.contributor.author | Ozsurekci, Yasemin | |
dc.contributor.author | Cengiz, Ali Bulent | |
dc.contributor.author | Kara, Ates | |
dc.contributor.author | Ceyhan, Mehmet | |
dc.date.accessioned | 2019-12-10T10:39:15Z | |
dc.date.available | 2019-12-10T10:39:15Z | |
dc.date.issued | 2017 | |
dc.identifier.issn | 2164-5515 | |
dc.identifier.uri | https://doi.org/10.1080/21645515.2016.1256519 | |
dc.identifier.uri | http://hdl.handle.net/11655/14107 | |
dc.description.abstract | A breakthrough infection occurring with 13-valent pneumococcal conjugate vaccine (PCV13) in Turkey are previously described. A breakthrough infection is defined as IPD in a child who had received 1 PCV-7 or PCV-13 and for which the pneumococcal isolate was a vaccine serotype. During one year period, among 6 patients with invasive pneumococcal infection, 2 patients were considered to have a vaccine failure with serotype 19F. Antibiotic resistance results were remarkable; macrolide resistance were observed in all strains except one, and high and intermediate penicillin resistance were determined in 2 strains. | |
dc.language.iso | en | |
dc.publisher | Taylor & Francis Inc | |
dc.relation.isversionof | 10.1080/21645515.2016.1256519 | |
dc.rights | info:eu-repo/semantics/openAccess | |
dc.subject | Biotechnology & Applied Microbiology | |
dc.subject | Immunology | |
dc.title | Invasive Pneumococcal Disease: From a Tertiary Care Hospital in the Post-Vaccine Era | |
dc.type | info:eu-repo/semantics/article | |
dc.type | info:eu-repo/semantics/publishedVersion | |
dc.relation.journal | Human Vaccines & Immunotherapeutics | |
dc.contributor.department | Çocuk Sağlığı ve Hastalıkları | |
dc.identifier.volume | 13 | |
dc.identifier.issue | 4 | |
dc.identifier.startpage | 962 | |
dc.identifier.endpage | 964 | |
dc.description.index | WoS | |
dc.description.index | Scopus | |